With a difficult to treat aetiology, multivariate complexity, and rising incidence rates in recent years, obesity is a complicated and multifaceted disease. Clinical, pharmacological, and surgical procedures are all part of the treatment. If those don't work, they'll be combined. One of these surgical procedures is the Roux-en-Y Gastric Bypass (RYGB), in which the stomach is cut in half, forming a tiny pouch, and the remaining stomach is excluded and denied endoscopic access to assess the outcomes of modified RYGB with extended pouch and endoscopic access to the unreconstructed stomach. Patients seen at the Alberto Rassi General State Hospital of Goiania (HGG) who were determined to be candidates for bariatric and metabolic surgery by the medical and multidisciplinary team were used as the sample population for a prospective clinical trial. The research was carried out between January 2020 and August 2021. The medical and interdisciplinary team interviewed the chosen patients to obtain their clinical histories and the results of their laboratory tests. The study has twelve participants in it. The mean age of these was 46.3 years, with 11 of them (91.7%) being female. Prior to surgery, the patient weighed 112.17 kg (92.00–150.00), and their BMI was
44.89. (35.06-74.39). Following surgery, the average weight was 80.77 kg (11.92 pounds) and the average BMI was 29.46 (11.00 pounds), both of which had significantly decreased (p=0.003 and p=0.002, respectively). At 12 months after surgery, endoscopic examinations of the pouch, residual stomach, and duodenum were performed on all patients. The average amount of extra weight removed was 68.21%. We come to the conclusion that the suggested modifications to RYGB (GBLP+GIB- Roux-en-Y gastric bypass with long pouch and gastrointestinal bipartition) did not impair weight loss or control of type 2 diabetes and other comorbidities and demonstrated to be a safe and effective alternative without gastroduodenal exclusion, enabling a better postoperative follow-up.
